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Introduction
Achromobacter xylosoxidans is a rare cause of
bacteremia; however patients with underlying illness,
especially malignancies, are at increased risk of
infection. Antibiotic therapy against this pathogen can
be difficult owing to its inherent resistance to multiple
common antibiotics.

Case Presentation
A 69-year-old male with adenocarcinoma of
the colon status post right hemicolectomy and
chemotherapy presented with fever and fatigue 10
days following endoscopic retrograde cholangiopancreatography (ERCP) with biliary stent placement
for new liver metastases. The patient had undergone
partial hemicolectomy and had completed 12 cycles
of adjuvant FOLFOX (leucovorin, 5-fluorouracil, and
oxaliplatin) at the time of initial diagnosis. Two years
following the completion of chemotherapy, the patient

was found to have obstructive jaundice and new
liver metastases on CT scan. He underwent an ERCP
procedure with biliary stenting for palliation and was
discharged home.
Ten days following the procedure, the patient
presented with complaints of fever to 102 oF and
fatigue. Vital signs revealed a fever of 101.3oF but were
otherwise unremarkable. Physical examination revealed
improvement of his jaundice, normal cardiopulmonary
examination, and right upper quadrant tenderness.
Despite four days of vancomycin and piperacillintazobactam, the patient continued to be febrile to
102.5oF.

Differential Diagnosis
The medical team remained concerned about infectious
etiologies, including cholangitis, bacteremia, and
endocarditis. Non-infectious causes of his fever were

Table 1. Antibiotic sensitivities (represented as percent susceptible) of Achromobacter xylosoxidans in several case
reports and the current patient’s susceptibilities.
Antibiotic

Turel O, et al.
(34 isolates)

Glupczynski Y, et al.
(37 isolates)

Current Patient

Antibiotic
Trimethoprim-Sulfamethoxazole

100

67

Unknown

Meropenem

100

100

Susceptible

Piperacillin-Tazobactam

91

91

Resistant

Ciprofloxacin

82

0

Susceptible

Ceftazidime

82

81

Resistant

Cefepime

15

0

Unknown

Gentamicin

0

0

Intermediate

*Turel O, et al. isolates were from a neonatal intensive care unit in Turkey, while Glupczynski, et al. isolates were from a single hospital in Belgium.
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also considered, such as post-ERCP pancreatitis, deep
venous thrombosis, and malignancy-related fever.

Outcome and Follow-up
Routine laboratory studies were unremarkable,
including serum amylase and lipase. Right upper
quadrant ultrasound and CT scan of the abdomen
and pelvis did not show any visible infectious source.
Transthoracic echocardiogram was not consistent
with endocarditis. Lower extremity Dopplers were
negative, and while upper extremity Dopplers revealed
no deep venous thrombosis, they did show a right
cephalic vein clot. Blood cultures drawn on admission
were found to be positive for gram-negative bacilli on
hospital day three. Subsequent blood cultures drawn
after the initiation of broad-spectrum antibiotics
were also positive for gram-negative bacilli. Prior to
speciation, the Infectious Disease team recommended
discontinuing vancomycin and switching the
piperacillin-tazobactam to meropenem. On hospital
day number seven, the patient became afebrile and
blood culture speciation revealed Achromobacter
xylosoxidans with sensitivities listed in Table 1. Blood
cultures drawn after the adjustment of antibiotic
therapy to meropenem remained negative. It was
believed that the patient had a transient bacteremia
of Achromobacter xylosoxidans related to the ERCP
that had seeded his cephalic vein thrombus, leading to
persistent bacteremia. Based on culture sensitivities, the
patient’s antibiotics were changed to oral ciprofloxacin
to complete a four week course of antibiotics. He was
also started on prophylactic enoxaparin for his cephalic
vein thrombus and was discharged home.

Discussion
Bacteremia due to A. xylosoxidans remains rare,
yet patients with underlying illness, particularly
malignancies, are at increased risk of infection.
Other predisposing conditions include cardiovascular
disease, renal failure, and immune suppression. 1
Though A. xylosoxidans is not a typical component
of endogenous human flora, it is known to inhabit
aqueous environments with common sources
including contaminated water and IV fluids, intravenous
catheters, humidification fluids, and instrumentation
utilized during surgical interventions.1
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Common symptoms of A. xylosoxidans bacteremia
include fever, fatigue, and persistence of symptoms
despite broad-spectrum antibiotic therapy. A unique
symptom to this presentation was right upper quadrant
abdominal pain consistent with a gastrointestinal source
of infection secondary to the patient’s prior ERCP. Aside
from gastrointestinal infections, other common sources
of infection include catheter-associated infections and
pneumonia.1
As A. xylosoxidans bacteremia is often associated
with specific predisposing conditions and sources of
infection, early identification of risk factors for infection
remains a crucial component of diagnosis. Initial
diagnostic tests to determine if the bacteremia is due
to A. xylosoxidans include repeating blood cultures
which may demonstrate sustained gram-negative
rod bacteremia. Another useful part of the diagnostic
work-up includes identifying the original source of
the patient’s bacteremia in addition to ongoing site of
infection. In this case, ultrasound served to localize a
right cephalic vein clot as the probable ongoing site of
infection; this clot had likely been seeded by a gastrointestinal source around the time of the ERCP procedure.
Choosing antibiotic therapy to treat A. xylosoxidans
bacteremia proves challenging because of its inherent
resistance to multiple antibiotics in addition to its
ability to harbor and horizontally transfer resistance
genes (Table 1). A proposed transfer mechanism for
A. xylosoxidans has been shown to potentially involve
integrons, R plasmids, and insertion sequences.2-4
A. xylosoxidans remains an important emerging cause
of nosocomial and community-acquired infections
because of its resistance to multiple antibiotics. Although
individual patterns vary, most strains of A. xylosoxidans
are resistant to aminoglycosides and quinolones. 2
The majority of isolates have demonstrated susceptibility to tazobactam, imipenem and meropenem, but
as demonstrated in Table 1, this patient harbored a
strain that was also resistant to piperacillin-tazobactam.
Aggressive measures to sterilize hospital solutions and
equipment, as well as to enforce policies to prevent
antibiotic misuse, should be employed to prevent future
cases of Achromobacter xylosoxidans bacteremia and
to quell the propagation of drug resistance in this
pathogen.

Key Points
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